Dendritic Cell-based Immunotherapy for Advanced Solid Tumours of Children and Young Adults

• Status: Completed
• Trial end date: 2019-05-27
• Target enrollment: 0
• Participant gender: All

Summary

Phase I/II, open, prospective clinical trial, historically controlled. The objective is to evaluate the safety and, as a secondary measure, the efficacy of an experimental treatment based on a cellular therapy (vaccination with autologous dendritic cells pulsed with tumor lysate) in patients affected of metastatic or relapsed sarcomas or (Central Nervous System) CNS tumors.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Clinica Universidad de Navarra, Universidad de Navarra

Criteria

Inclusion Criteria:

• Signed informed consent

• Diagnosis or metastatic or relapsed sarcoma or high grade central nervous system tumor

• From 3 to 40 years

• Surgery feasibility. In the central nervous system tumors, residual tumor after surgery must be minimal.

Exclusion Criteria:

• Toxicity or liver, medullar, renal insufficiency that advise against participation

• Pregnant or breast feeding women

• Diagnosis of other tumor than basal cell squamous carcinoma of the skin or in situ cervix carcinoma

• Immunosuppressive treatment

• Human Immunodeficiency virus (HIV), hepatitis B, hepatitis C or syphilis infection